poisar

Stocks · News reference

What's Going On With Amgen Stock Tuesday?

BenzingaVandana Singh

AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncPrecedence Research

    Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing

    The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.

  2. Globenewswire IncPrecedence Research

    Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

    The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

  3. Globenewswire IncNovartis

    Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

    The FDA approved Novartis's Cosentyx (secukinumab) 150 mg for treating polymyalgia rheumatica in adults with inadequate response to or intolerance of corticosteroids. In the Phase III REPLENISH trial, Cosentyx doubled sustained remission rates (40.5% vs 20.5%) compared to placebo and demonstrated steroid-sparing effects. This marks the 11th US indication for Cosentyx and the first anti-IL-17 biologic approved for PMR, offering an alternative to long-term steroid use which carries significant health risks.

  4. Globenewswire IncPrecedence Research

    Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035

    The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.